Document is current
Any future updates will be listed below
-
Authors
Schmidt, Julien
Chiffelle, Johanna https://orcid.org/0000-0002-8312-2681
Perez, Marta A. S. https://orcid.org/0000-0002-3963-5965
Magnin, Morgane https://orcid.org/0000-0002-9808-8973
Bobisse, Sara
Arnaud, Marion https://orcid.org/0000-0003-0534-2379
Genolet, Raphael https://orcid.org/0000-0001-9335-3945
Cesbron, Julien
Barras, David https://orcid.org/0000-0001-8985-4704
Navarro Rodrigo, Blanca
Benedetti, Fabrizio https://orcid.org/0000-0002-9959-9142
Michel, Alexandra
Queiroz, Lise
Baumgaertner, Petra https://orcid.org/0000-0002-5979-7654
Guillaume, Philippe
Hebeisen, Michael
Michielin, Olivier
Nguyen-Ngoc, Tu https://orcid.org/0000-0001-7574-2947
Huber, Florian https://orcid.org/0000-0002-2585-9079
Irving, Melita
Tissot-Renaud, Stéphanie
Stevenson, Brian J.
Rusakiewicz, Sylvie
Dangaj Laniti, Denarda https://orcid.org/0000-0002-5659-6427
Bassani-Sternberg, Michal https://orcid.org/0000-0002-1934-954X
Rufer, Nathalie
Gfeller, David
Kandalaft, Lana E. https://orcid.org/0000-0002-1575-6674
Speiser, Daniel E. https://orcid.org/0000-0003-2031-3250
Zoete, Vincent
Coukos, George https://orcid.org/0000-0001-8813-7367
Harari, Alexandre https://orcid.org/0000-0002-1055-2090
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_182384 and CRSII5_193749)
- License Information
-
More Information
Article History
Received: 21 June 2022
Accepted: 23 May 2023
First Online: 6 June 2023
Competing interests
: G.C. has received grants, research support or is coinvestigator in clinical trials by Bristol-Myers-Squibb, Celgene, Boehringer Ingelheim, Tigen, Roche, Iovance and Kite. G.C. has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure and GeneosTx. G.C. has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T cell expansion and engineering for T cell therapy. G.C. receives royalties from the University of Pennsylvania. S.B. and A.H. have patents in technologies related to T cell expansion and engineering for T cell therapy. Other authors declare no competing interests.
